Short Interest in LifeVantage Co. (NASDAQ:LFVN) Drops By 5.4%

LifeVantage Co. (NASDAQ:LFVN) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 191,800 shares, a decline of 5.4% from the December 15th total of 202,800 shares. Currently, 1.9% of the company’s shares are sold short. Based on an average daily volume of 110,600 shares, the days-to-cover ratio is presently 1.7 days.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Lake Street Capital assumed coverage on shares of LifeVantage in a research note on Thursday, December 19th. They set a “buy” rating and a $26.00 price objective for the company. Craig Hallum assumed coverage on shares of LifeVantage in a research note on Tuesday, January 14th. They set a “buy” rating and a $35.00 price objective for the company.

LifeVantage Trading Up 0.0 %

NASDAQ LFVN opened at $25.31 on Friday. The company’s fifty day simple moving average is $16.74 and its 200-day simple moving average is $12.12. LifeVantage has a 52 week low of $5.22 and a 52 week high of $27.38. The stock has a market cap of $316.88 million, a P/E ratio of 79.10 and a beta of 0.82.

LifeVantage (NASDAQ:LFVN) last posted its earnings results on Tuesday, October 29th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%. The business had revenue of $47.21 million for the quarter.

LifeVantage Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were given a dividend of $0.04 per share. The ex-dividend date was Monday, December 2nd. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.63%. LifeVantage’s payout ratio is currently 50.00%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Capital Management Corp VA bought a new position in LifeVantage during the 3rd quarter valued at $5,073,000. HighTower Advisors LLC bought a new position in LifeVantage during the 3rd quarter valued at $638,000. Ritholtz Wealth Management boosted its stake in LifeVantage by 65.2% during the 4th quarter. Ritholtz Wealth Management now owns 47,348 shares of the company’s stock valued at $830,000 after acquiring an additional 18,682 shares during the last quarter. Renaissance Technologies LLC boosted its stake in LifeVantage by 2.1% during the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after acquiring an additional 17,300 shares during the last quarter. Finally, Barclays PLC boosted its stake in LifeVantage by 38.2% during the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after acquiring an additional 11,608 shares during the last quarter. 35.32% of the stock is owned by institutional investors and hedge funds.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.